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Background: Glucagon-like peptide-1 (GLP-1), a gut-derived incretin hormone secreted in a nutrient-dependent manner, stimulates insulin 
secretion and reduces postprandial glycemia. Previous studies have demonstrated that the incretin effect is substantially reduced in patients with 
type 2 diabetes. Impaired glucose tolerance (IGT), the pre-stage of diabetes, is an important therapeutic target to reduce cardiovascular events, 
however, the impact of incretin effect in patients with IGT remains to be elucidated. The aim of this study was to evaluate whether incretin action as 
assessed by changes in plasma GLP-1 levels during oral glucose tolerance test (OGTT) is reduced even in non-diabetic subjects with IGT.
Methods: We measured plasma GLP-1 levels during a 75 g OGTT in 13 non-diabetic patients with coronary artery disease. Blood samples for GLP-1 
were collected before and 2-hour after OGTT, using specific sample tubes containing dipeptidyl peptidase-4 inhibitor to avoid the rapid degradation 
of GLP-1. Plasma GLP-1 levels were measured with specific commercially available ELISA kits.
Results: Mean fasting GLP-1 level was 4.5 pmol/L, and mean 2-hour postprandial GLP-1 level increased to 8.7 pmol/L. There were no significant 
correlation between fasting levels of GLP-1 and glucose (r=0.06, p=0.84), and 2-hour postprandial levels of GLP-1 and glucose (r=-0.37, p=0.23). 
On the other hand, the rate of increase in GLP-1 (2-hour GLP-1 divided by fasting GLP-1) correlated inversely with 2-hour glucose levels (r=-0.66, 
p=0.01). Patients with IGT had similar baseline characteristics to those with normal glucose tolerance (NGT). Although fasting GLP-1 (5.2 vs 2.4 
pmol/L, p=0.28) and 2-hour postprandial GLP-1 levels (8.2 vs 10.2 pmol/L, p=0.63) were comparable between IGT and NGT, the rate of increase in 
GLP-1 level was significantly lower in IGT than in NGT (1.7 vs 4.6, p=0.02).
Conclusions: The rate of increase in plasma GLP-1 level during a 75 g OGTT correlates inversely with postprandial glucose level and is reduced in 
IGT as compared with NGT. Our results suggest that therapeutic approaches for enhancing incretin action can ameliorate glucose intolerance even in 
non-diabetic subjects with IGT.
